Prime Medicine prices $125 million public stock offering at $3.50 per share
Prime Medicine Inc. announced an underwritten public offering of 35,714,286 common shares at $3.50 each, targeting gross proceeds of about $125 million. The company gave underwriters a 30‑day option to purchase up to roughly 5.4 million additional shares. Jefferies, TD Cowen and Goldman Sachs are serving as joint book‑running managers. The transaction is slated to close around 12 November 2026, subject to standard closing conditions.
Why it matters
The company says the cash will be used to advance its gene‑editing therapy programs and other R&D initiatives. Existing shareholders may experience dilution from the new shares and any exercised option.
Key facts
- 135,714,286 shares were priced at $3.50 each. investing.com
- 2Gross proceeds are expected to be approximately $125 million before underwriting costs. investing.com
- 3Underwriters received a 30‑day option to buy up to 5,357,142 additional shares. investing.com
- 4Closing is anticipated on or about 12 November 2026, subject to customary closing conditions. investing.com
- 5Jefferies, TD Cowen and Goldman Sachs & Co. LLC are joint book‑running managers; Oppenheimer & Co. and LifeSci Capital act as passive managers. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.